CGTLive’s Weekly Rewind – September 2, 2022

Article

Review top news and interview highlights from the week ending September 2, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Iovance Starts BLA Submission of Lifileucel for Advanced Melanoma

The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.

2. CARsgen Advances Autologous CAR T Therapies in Multiple Myeloma, Advanced Gastric Cancer

The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.

3. Mark Forman, MD, PhD, on ICM Administration of Gene Therapy in Frontotemporal Dementia

The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.

4. FDA Recognizes CRISPR Therapy for Treatment of Hereditary Angioedema

The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.

5. Phase 3 Heart Failure Cell Therapy Trial Receives Go-Ahead from DSMB

The risk-benefit assessment determined that there are no significant safety concerns.

Related Videos
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Mark Walters, MD
© 2024 MJH Life Sciences

All rights reserved.